The prevalence of myopia is estimated to be 2.6 billion people worldwide and the percentage of individuals with sight-threatening high myopia (≤ -6 diopters) is increasing. Myopia is primarily caused by excessive axial elongation of the eyeball, and treatment modalities attempt to reduce this progression. While increased outdoor time is known to delay myopia onset, new pharmacological and optical interventions aim to reduce myopia progression. This review finds that these promising interventions are expected to significantly decrease the future prevalence of sight-threatening high myopia.